Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Korsana Biosciences to Participate in Upcoming Investor Conferences

By GlobeNewswire

WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Korsana Biosciences, Inc. (“Korsana” or the “Company”) (Nasdaq: KRSA), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences.

  • Guggenheim 3rd Annual Healthcare Innovation Conference: Fireside chat on Monday, November 9, 2026, at 10:00 a.m. ET in Boston, MA.
  • Stifel 2026 Healthcare Conference: Fireside chat on Tuesday, November 10, 2026, at 1:20 p.m. ET in New York, NY.
  • UBS Global Biopharma Conference 2026: Fireside chat on Monday, November 16, 2026, at 3:20 p.m. GMT in London, UK.
  • Jefferies London Healthcare Conference: Presentation on Tuesday, November 17, 2026, at 3:00 p.m. GMT in London, UK.

Live webcasts of the presentations will be available in the Investors section of the Company’s website at https://investors.korsana.com/news-events/events-presentations. Replays of the webcasts will be archived on the Company’s website for 90 days following the events.

About Korsana Biosciences
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com and follow the Company on LinkedIn.

Investor and Media Contact:
Eva Stroynowski
IR@korsana.com
Media@korsana.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.